Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076)

Although bevacizumab (Avastin(®)) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simultaneous blocking of several proangiogenic factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Jong-Hee, Kwon, Hyuk-Sang, Kim, Bomin, Min, Gihong, Shin, Chorong, Yang, Seok-Woo, Lee, Seong Wook, Lee, Youngmin, Hong, Dahae, Kim, Yong-Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356919/
https://www.ncbi.nlm.nih.gov/pubmed/32560565
http://dx.doi.org/10.3390/biom10060919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356919/
https://www.ncbi.nlm.nih.gov/pubmed/32560565
http://dx.doi.org/10.3390/biom10060919

Ejemplares similares